Skip to content
MENU
SELECTED
PUBLICATIONS
2024
Tumor suppressor let-7 acts as a key regulator for pluripotency gene expression in Muse cells
LEARN MORE
2023
Comparison of the Anti-Inflammatory Effects of Mouse Adipose- and Bone-Marrow-Derived Multilineage-Differentiating Stress-Enduring Cells in Acute-Phase Spinal Cord Injury
LEARN MORE
2023
Fetal Muse-based therapy prevents lethal radio-induced gastrointestinal syndrome by intestinal regeneration
LEARN MORE
2023
Role of glycosphingolipid SSEA-3 and FGF2 in the stemness and lineage commitment of multilineage differentiating stress enduring (MUSE) cells
LEARN MORE
2022
Endogenous reparative pluripotent Muse cells with a unique immune privilege system: Hint at a new strategy for controlling acute and chronic inflammation
LEARN MORE
2022
Naïve pluripotent-like characteristics of non-tumorigenic Muse cells isolated from human amniotic membrane
LEARN MORE
Page
1
Page
2
Page
3
Page
4
Page
5
Clinical Trials & Clinical Data
2024
Accumulation of endogenous Muse cells in the myocardium and its pathophysiological role in patients with fulminant myocarditis
LEARN MORE
2024
Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial)
LEARN MORE
2024
Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial
LEARN MORE
2024
Donor Muse Cell Treatment Without HLA-Matching Tests and Immunosuppressant Treatmen
LEARN MORE
2023
Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial
LEARN MORE
2023
Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke
LEARN MORE
Page
1
Page
2
Page
3
NEWS
2024
Muse Cells: A New Stem Cell Treatment
LEARN MORE
Home
Our Science
About
Publications
Contact
Home
Our Science
About
Publications
Contact
